Peer-Reviewed Phase 2 Data for Lorundrostat Shows Significant Blood Pressure and Albuminuria Reductions in CKD

Mineralys Therapeutics shares gained in premarket after Phase 2 Explore-CKD results for lorundrostat were published, showing significant blood pressure and albuminuria reductions.